Page last updated: 2024-09-04

ezetimibe and evacetrapib

ezetimibe has been researched along with evacetrapib in 3 studies

Compound Research Comparison

Studies
(ezetimibe)
Trials
(ezetimibe)
Recent Studies (post-2010)
(ezetimibe)
Studies
(evacetrapib)
Trials
(evacetrapib)
Recent Studies (post-2010) (evacetrapib)
2,4845631,465752072

Protein Interaction Comparison

ProteinTaxonomyezetimibe (IC50)evacetrapib (IC50)
Cholesteryl ester transfer proteinHomo sapiens (human)0.11

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Ballantyne, CM; Catapano, AL; Norata, GD1
Ballantyne, CM; Beacham, LA; Miller, DL; Nicholls, SJ; Nissen, SE; Ray, KK; Riesmeyer, JS; Ruotolo, G1
Carvajal-Gonzalez, S; Dullea, R; Furtado, JD; Nicholls, SJ; Ruotolo, G; Sacks, FM1

Reviews

1 review(s) available for ezetimibe and evacetrapib

ArticleYear
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.
    European heart journal, 2013, Volume: 34, Issue:24

    Topics: Azetidines; Benzimidazoles; Benzodiazepines; Carrier Proteins; Cholesterol, LDL; Dicarboxylic Acids; Dyslipidemias; Ezetimibe; Fatty Acids; Humans; Hypolipidemic Agents; Lipoprotein(a); Oligonucleotides; Oxazolidinones; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases

2013

Trials

2 trial(s) available for ezetimibe and evacetrapib

ArticleYear
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
    Atherosclerosis, 2017, Volume: 261

    Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzodiazepines; Biomarkers; Cholesterol Ester Transfer Proteins; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Middle Aged; Time Factors; Treatment Outcome; United States

2017
Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.
    Arteriosclerosis, thrombosis, and vascular biology, 2022, Volume: 42, Issue:2

    Topics: Aged; Anticholesteremic Agents; Apolipoprotein C-III; Atorvastatin; Benzodiazepines; Cholesterol Ester Transfer Proteins; Coronary Disease; Ezetimibe; Female; Heart Disease Risk Factors; Humans; Hyperlipidemias; Lipoproteins, HDL; Male; Middle Aged

2022